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Hundreds of direct materials are used for each biologic production process.  Vendor initiated changes (VIC) to 
the production process, packaging, raw material sources, and other aspects of these direct materials can and 
will happen. Each change could have the potential for both process and product impact not only to one product, 
but to every product that uses it across a manufacturing network.  In order to ensure these changes are 
assessed appropriately and in a timely manner, procedures and processes need to be in place both from the 
customer and supplier.  In addition, if changes are complex, communication between both parties is often 
necessary.  Complex changes may also require a deeper level of collaboration between multiple functional 
groups from the customer and supplier.  This poster will describe Roche/Genentech’s approach for technical 
assessments of VICs to ensure they are evaluated properly by the necessary subject matter experts (SMEs).  It 
will highlight case studies such as a complex VIC pertaining to Poloxamer 188 (P188) and the effective 
collaboration between Roche/Genentech and its supplier.   
 
Poloxamer 188 is a complex nonionic tri-block co-polymer composed of a central hydrophobic chain of 
polyoxypropylene (PPO) flanked by two hydrophilic chains of polyoxyethylene (PEO) which is used in 
biopharmaceutical manufacturing for the cultivation of mammalian cells.  The supplier informed 
Roche/Genentech of a production site change of P188 through the VIC business process.  The complexity 
associated with the site change VIC was further compounded by an ongoing investigation based on observed 
low cell growth and product yield for some large-scale biomanufacturing processes at Roche/Genentech.  Lot-
to-lot variability in P188 was identified as the primary source of the observed low growth and yield even though 






Coupled with this investigation and the supplier initiated site change, it provided the opportunity for a 
collaboration to understand the causal elements of P188 lot variability and to ensure that measures and controls 
were identified and implemented for consistent P188 production. 
 
 
